Bookmark

Add to MyYahoo RSS

Celgene News

News on Celgene (Ticker: CELG) continually updated from thousands of sources around the net.

Friday Jul 25 | TheStreet.com

Will This Price Target Increase Help Celgene (CELG) Stock Today?

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Mozilla, TheStreet

Friday Jul 25 | BioSpace

Flexion Therapeutics Announces Board Changes

Flexion Therapeutics, Inc. announced today changes to the composition of its Board of Directors.

Comment?

Related Topix: Biotech, Healthcare Industry

Thu Jul 24, 2014

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Sales grew 4.9 percent yea... )--Coca-Cola Enterprises, Inc. today reported second-quarter operating income of $295 million on a reported basis, or $341 million on a comp... )--Celgene Corporation reported net product sales of $1,845 million for the second quarter of 2014, an 18 percent increase from the same period in 2013.

Comment?

Related Topix: Manufacturing, 3M, Chemicals, MMM, Beverages, CocaCola Enterprises, Biotech, Medicine, Healthcare Industry, Build-A-Bear Workshop, Marketing Workshop, Advertising

MarketWatch

Biotechs beat estimates, but the Street wants more

It's not easy being a biotech company these days. Just ask Alexion Pharmaceuticals Inc., Celgene Corp. and Gilead Sciences Inc. blew past earnings expectations when it reported late Wednesday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Gilead Sciences

Seeking Alpha

Celgene's (CELG) CEO, Robert Hugin on Q2 2014 Results - Earnings Call Transcript

Good morning and welcome to the Celgene Second Quarter 2014 Earnings conference call.

Comment?

Related Topix: Biotech, Medicine, Celgene, Healthcare Industry, Oncology, Hematology

Seeking Alpha

Why Gilead Is A Better Buy Than This Rival

We pitch two companies from the biotechnology sector, Gilead and Celgene, against one another in the latest installment of our Head-To-Head series.

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Healthcare Industry, Celgene, HIV/AIDS

TheStreet.com

Celgene (CELG) Stock Falls After Mixed Second-Quarter Earnings

Celgene reported a year-over-year increase in net profit to $597.8 million, or 72 cents a share, from $478.1 million, or 56 cents a share.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Science / Technology

Reuters

Celgene profit rises 25 pct up on higher cancer drug sales

Celgene Corp reported a 25 percent increase in quarterly profit, helped by robust sales of its flagship cancer drug, Revlimid.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Investor's Business Daily

Celgene Reports Second Quarter 2014 Operating and Financial Results

Celgene Corporation reported net product sales of $1,845 million for the second quarter of 2014, an 18 percent increase from the same period in 2013.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Celgene

Seeking Alpha

Cramer's Mad Money: The 4 Horsemen Trample Big Pharma

The Four Horsemen Are Trampling Over Big Pharma: Regeneron , Gilead , Biogen Idec , Celgene , GlaxoSmithKline The days of big pharma names like GlaxoSmithKline may be giving way to smaller, stronger biotechs, such as Cramer's "Four Horsemen": Regeneron , Gilead , Biogen Idec and Celgene .

Comment?

Related Topix: Biotech, Medicine, Gilead Sciences, Regeneron Pharmaceuticals, Biogen Idec, Healthcare Industry, GlaxoSmithKline, Celgene

Wed Jul 23, 2014

The Motley Fool

Earnings Preview: Bristol-Myers Squibb and Celgene Corporation

Most health care stocks have been experiencing a roller coaster ride so far this year.

Comment?

Related Topix: Bloomsbury Publishing, Bristol Myers Squibb, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals, Biotech, Medicine, Healthcare Industry

Business Journal

Biogen's great earnings could spur more inflated biotech stock prices

If second quarter earnings reported tonight by Gilead , and tomorrow morning by Celgene , are as good as what we saw from Biogen Idec this morning, you can bank on a reinflation of the biotech bubble for the next several months to come.

Comment?

Related Topix: Biotech, Science / Technology, Medicine, Gilead Sciences, Healthcare Industry, Celgene, Biogen Idec, Summit, NJ

AmericanBankingNews.com

Celgene (CELG) Scheduled to Post Earnings on Thursday

Celgene is set to post its Q214 quarterly earnings results on Thursday, July 24th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Celgene, Stanley

Tue Jul 22, 2014

TheCelebrityCafe

Scientists find that cancer-fighting drug romidepsin aids in detection of HIV

Scientists from Aarhus University in Demark have found that cancer-fighting Istodax, also known as romidepsin and produced by Celgene Corp., activates the HIV virus that hides in CD4 cells.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Fri Jul 18, 2014

Benzinga

Biotech Enters Reporting Season With Large Caps Central To Sector Performance

Biotech stock stocks enter their earnings season with investors increasingly interested in the long-term outlook for product pipelines, although large-cap growth stocks remain central to the sectors performance, an analyst said Friday.

Comment?

Related Topix: Financial Markets, Biotech, Biogen Idec, Hemophilia, Health, Medicine, Gilead Sciences, Healthcare Industry, Startups

Wed Jul 16, 2014

Seeking Alpha

Some Elegant Biotech Platforms I Read About While Looking For The Next Regeneron

Discovery and development platforms can efficiently multiply a drug pipeline. Regeneron leveraged its platforms to become a biotech paragon over the 5 years prior to 2014.

Comment?

Related Topix: Biotech, Medicine, Regeneron Pharmaceuticals, Healthcare Industry, Sangamo Biosciences, Startups, Genetics, Biology, Science, Celgene

Thu Jul 10, 2014

Seeking Alpha

Cramer's Mad Money - The 4 Horsemen Of Biotech Ride On

Cramer consulted the technical analysis of Bob Lang to see what the charts are saying about the "Four Horsemen of Biotech": Celgene , Regeneron , Biogen Idec and Gilead .

Comment?

Related Topix: Biotech, Medicine, Celgene, Regeneron Pharmaceuticals, Healthcare Industry, Gilead Sciences, Financial Markets, Williams Companies, Energy, Oil & Gas

Wed Jul 09, 2014

Value Line

Stock Market Today: July 9, 2014

Stocks to Watch from The Survey - Second-quarter earnings season kicked off after the market closed yesterday, when Alcoa released June-period financials.

Comment?

Related Topix: Financial Markets, Bob Evans Farms, Restaurant Management, Biotech, Medicine, Celgene, Healthcare Industry

Benzinga

Two Analysts Don't See Celgene's Weak Trial Results As A Huge Setback

Shares of Celgene have been volatile since the company announced weak Phase III trial results for OTEZLA Wednesday morning.

Comment?

Related Topix: Celgene, Biotech, Medicine, Healthcare Industry

BioSpace

Celgene Corporation's OTEZLA Misses Mark In Phase 3 Spinal Arthritis Study

Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLAA in Ankylosing Spondylitis Phase III POSTURE Study Did Not Achieve Primary Endpoint of ASAS 20 at Week 16 Based on Efficacy and Safety Data at Week 24, the Independent Data Monitoring Committee Recommended Continuation of the Phase III POSTURE Study Without Change In ... (more)

Comment?

Related Topix: Biotech, Medicine, Arthritis, Health, Healthcare Industry, Celgene, Psoriatic Arthritis, Healthcare Law, Law

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••